Harriet Lefton

About the Author Harriet Lefton

Harriet originates from the UK where she worked as a journalist specializing in the metal markets. She graduated from the University of Cambridge before becoming a qualified UK lawyer.

2 Pharmaceutical Stocks That Can Double in a Year: Global Blood Therapeutics Inc (GBT), TherapeuticsMD Inc (TXMD)

These two pharma stocks all have upside of over 100% say top Wall Street analysts.

For investors looking for huge returns, pharmaceutical stocks may well be the answer. While these stocks are inevitably risky with a lot riding on key clinical results, if trials succeed, the results can be spectacular.

Smaller stocks can also be snapped up by big pharma — see the $12 billion purchase of Kite Pharma by Gilead Sciences which caused KITE shares to rise by 29%.

But the riskier the stock, the more important it becomes to check all possible data signals. Here we used TipRanks stock screener to pinpoint healthcare stocks with a ‘Strong Buy’ analyst consensus rating. Applying these filters (Strong Buy, healthcare sector) led to an extensive list of hot stocks.

You can easily hone in on stocks that stand out from the crowd by looking at the average analyst price target. I scanned for stocks with recent buy ratings and upside potential of over 100%.

Let us dig further down into each stock and discover just why analysts are so bullish on these two top stocks:

Hot Pharmaceutical Stocks: Global Blood Therapeutics (GBT)

A clinical stage biopharma Global Blood Therapeutics Inc (NASDAQ:GBT) is a top stock to track right now.

GBT focuses on developing and commercializing novel therapeutics for serious blood-based disorders with significant unmet need. At the moment, GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and pulmonary fibrosis.

The Street is very bullish on the stock’s prospects. GBT has seven buy ratings from analysts — all in the last three months, and no hold or sell ratings. We can also see that the stock has a $58.33 average analyst 12-month price target. Given that the stock is trading at $32.35, this works out at huge upside potential of 80%.

Five-star Cowen analyst Ritu Baral has the highest price target on GBT of $83 (195%). She is also the best analyst who has rated GBT in the last year. Indeed, across her 11 GBT ratings she has an 82% success rate and a 32.4% average return. She recently met with company management to discuss ongoing progress and upcoming milestones. Barel concludes that “development of lead drug GBT440 appears to be on track.”

Analysts anticipate that data from three ongoing trials of GBT440 will be revealed in 4Q17. Wedbush analyst Liana Moussatos says: “We believe positive results in these studies could dramatically increase the valuation of GBT.”

Hot Pharmaceutical Stocks: TherapeuticsMD (TXMD)

TherapeuticsMD Inc (NYSEAMERICAN:TXMD) is a unique biotech making waves in the world of female healthcare. The company develops and commercializes products exclusively for women. This approach clearly has the backing of the Street, as TXMD has a Strong Buy analyst consensus rating.

In fact, in the last three months, TherapeuticsMD has received five back-to-back buy ratings. Meanwhile the $15.80 average analyst price target represents a huge 208% upside from the $5.13 current share price. Crucially even the lowest price target of $10 from Oppenheimer’s Jay Olson on Aug. 29 still suggests huge upside potential of 67%.

The most bullish analyst of the pack is top Cantor Fitzgerald analyst William Tanner. He reiterated his TXMD buy rating on Aug. 14 with a $33 price target. This works out at huge 450% upside potential. Crucially, the analyst demonstrates a strong track record on the stock with a 78% success rate and 11.2% average return.

Tanner says TXMD’s lead product candidate, a TX-004 soft gel capsule “could be approved, with a Class 1 review (two months), in early 2018.” The approval relies on the current review of additional information by the Food and Drug Administration, which could come as soon as Nov. 3. Tanner concludes that “a dimly lit path is becoming brighter.” He adds that the extra information requested by the FDA surrounds a lack of long-term endometrial safety data and not more fundamental concerns on chemistry, efficacy or manufacturing.

And encouragingly, a Deutsche Bank-commissioned survey of 525 women showed a healthy TX-004 uptake among current Rx users, who appeared happy to switch to a new prescription if recommended by the doctor.